top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
Frontiers in crystal engineering [[electronic resource] /] / edited by Edward R.T. Tiekink, Jagadese J. Vittal
Frontiers in crystal engineering [[electronic resource] /] / edited by Edward R.T. Tiekink, Jagadese J. Vittal
Pubbl/distr/stampa Chichester, England ; ; Hoboken, NJ, : Wiley, c2006
Descrizione fisica 1 online resource (347 p.)
Disciplina 548
548.81
Altri autori (Persone) TiekinkEdward R. T
VittalJagadese J
Soggetto topico Molecular crystals - Research
Soggetto genere / forma Electronic books.
ISBN 1-280-44877-6
9786610448777
0-470-02261-2
0-470-02259-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Frontiers in Crystal Engineering; Contents; List of Contributors; Foreword; 1 Applications of Crystal Engineering Strategies in Solvent-free Reactions: Toward a Supramolecular Green Chemistry; 1 Introduction; 1.1 Making Crystals by Smashing Crystals?; 1.2 Milling, Grinding, Kneading and Seeding; 2 Mechanochemical Preparation of Hydrogen-Bonded Adducts; 3 Mechanically Induced Formation of Covalent Bonds; 3.1 Mechanochemical Preparation of Coordination Networks; 4 The Solvent-free Chemistry of the Zwitterion [CoIII(η5-C5H4COOH)(η5-C5H4COO)]; 5 Concluding Remarks; 6 Acknowledgments; References
2 Crystal Engineering of Pharmaceutical Co-crystals1 Introduction; 1.1 What Are Co-crystals?; 1.2 How Are Co-crystals Prepared?; 1.3 Why Are Co-crystals of Relevance in the Context of APIs?; 2 What Is the Origin of Polymorphism and Is It Prevalent in Co-crystals?; 3 What Is a Pharmaceutical Co-crystal?; 3.1 A Case Study: Pharmaceutical Co-crystals of Carbamazepine, 1 (CBZ, 1); 3.2 But Beware of "Fake" Pharmaceutical Co-crystals!; 4 Conclusions; 5 Acknowledgments; References; 3 Template-controlled Solid-state Synthesis: Toward a General Form of Covalent Capture in Molecular Solids
1 Introduction1.1 Target-oriented Organic Synthesis; 1.2 Target-oriented Organic Synthesis and Covalent Capture; 1.3 Overview; 2 Controlling Reactivity Using Linear Templates; 3 Template-controlled Solid-state Reactivity; 3.1 Template-controlled Reactivity in the Solid state; 3.2 Resorcinol as a Linear Template; 3.3 Modularity and Generality; 4 Target-oriented Organic Synthesis in the Solid State; 4.1 [2.2]-Paracyclophane; 4.2 Template Switching; 4.3 Ladderanes; 5 Other Linear Templates; 5.1 1,8-Naphthalenedicarboxylic Acid; 5.2 Bis-p-phenylene[34]-crown[10]
5.3 Carballylic and 1,2,4,5-Benzenetetracarboxylic Acids5.4 Tetrakis(4-iodoperfluorophenyl)erythritol; 6 Summary and Outlook; References; 4 Interplay of Non-covalent Bonds: Effect of Crystal Structure on Molecular Structure; 1 Introduction; 2 Second-Sphere Coordination; 3 Soft Coordination Environments; 3.1 Mercury and Tin; 3.2 Comparison with Calculation; 3.3 Influence of Disorder; 4 Speciation; 5 Molecular Conformation; 6 Conclusions; References; 5 Crystal Engineering of Halogenated Heteroaromatic Clathrate Systems; 1 Introduction; 1.1 Clathrates; 1.2 New Clathrand Inclusion Hosts
1.3 Halogenated Heteroaromatic Hosts2 Aromatic Edge-Edge C-H· · ·N Dimers; 3 Heteroatom-1,3-Peri Interactions; 3.1 The Ether-1,3-Peri Aromatic Hydrogen Interaction; 3.2 The Thioether-and Aza-1,3-Peri Aromatic Hydrogen Interactions; 4 Molecular Pen Structures; 5 Halogenated Edge-Edge Interactions; 6 Pi-Halogen Dimer (PHD) Interactions; 6.1 A New Aromatic Building Block; 6.2 Staircase Inclusion Compounds; 6.3 Layer Inclusion Compounds; 7 Molecular Bricks, Spheres and Grids; 7.1 Bricks and Mortar Inclusion Systems; 7.2 Molecular Spheres of Variable Composition; 7.3 Interlocking Molecular Grids
8 Conclusions
Record Nr. UNINA-9910143744803321
Chichester, England ; ; Hoboken, NJ, : Wiley, c2006
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Frontiers in crystal engineering [[electronic resource] /] / edited by Edward R.T. Tiekink, Jagadese J. Vittal
Frontiers in crystal engineering [[electronic resource] /] / edited by Edward R.T. Tiekink, Jagadese J. Vittal
Pubbl/distr/stampa Chichester, England ; ; Hoboken, NJ, : Wiley, c2006
Descrizione fisica 1 online resource (347 p.)
Disciplina 548
548.81
Altri autori (Persone) TiekinkEdward R. T
VittalJagadese J
Soggetto topico Molecular crystals - Research
ISBN 1-280-44877-6
9786610448777
0-470-02261-2
0-470-02259-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Frontiers in Crystal Engineering; Contents; List of Contributors; Foreword; 1 Applications of Crystal Engineering Strategies in Solvent-free Reactions: Toward a Supramolecular Green Chemistry; 1 Introduction; 1.1 Making Crystals by Smashing Crystals?; 1.2 Milling, Grinding, Kneading and Seeding; 2 Mechanochemical Preparation of Hydrogen-Bonded Adducts; 3 Mechanically Induced Formation of Covalent Bonds; 3.1 Mechanochemical Preparation of Coordination Networks; 4 The Solvent-free Chemistry of the Zwitterion [CoIII(η5-C5H4COOH)(η5-C5H4COO)]; 5 Concluding Remarks; 6 Acknowledgments; References
2 Crystal Engineering of Pharmaceutical Co-crystals1 Introduction; 1.1 What Are Co-crystals?; 1.2 How Are Co-crystals Prepared?; 1.3 Why Are Co-crystals of Relevance in the Context of APIs?; 2 What Is the Origin of Polymorphism and Is It Prevalent in Co-crystals?; 3 What Is a Pharmaceutical Co-crystal?; 3.1 A Case Study: Pharmaceutical Co-crystals of Carbamazepine, 1 (CBZ, 1); 3.2 But Beware of "Fake" Pharmaceutical Co-crystals!; 4 Conclusions; 5 Acknowledgments; References; 3 Template-controlled Solid-state Synthesis: Toward a General Form of Covalent Capture in Molecular Solids
1 Introduction1.1 Target-oriented Organic Synthesis; 1.2 Target-oriented Organic Synthesis and Covalent Capture; 1.3 Overview; 2 Controlling Reactivity Using Linear Templates; 3 Template-controlled Solid-state Reactivity; 3.1 Template-controlled Reactivity in the Solid state; 3.2 Resorcinol as a Linear Template; 3.3 Modularity and Generality; 4 Target-oriented Organic Synthesis in the Solid State; 4.1 [2.2]-Paracyclophane; 4.2 Template Switching; 4.3 Ladderanes; 5 Other Linear Templates; 5.1 1,8-Naphthalenedicarboxylic Acid; 5.2 Bis-p-phenylene[34]-crown[10]
5.3 Carballylic and 1,2,4,5-Benzenetetracarboxylic Acids5.4 Tetrakis(4-iodoperfluorophenyl)erythritol; 6 Summary and Outlook; References; 4 Interplay of Non-covalent Bonds: Effect of Crystal Structure on Molecular Structure; 1 Introduction; 2 Second-Sphere Coordination; 3 Soft Coordination Environments; 3.1 Mercury and Tin; 3.2 Comparison with Calculation; 3.3 Influence of Disorder; 4 Speciation; 5 Molecular Conformation; 6 Conclusions; References; 5 Crystal Engineering of Halogenated Heteroaromatic Clathrate Systems; 1 Introduction; 1.1 Clathrates; 1.2 New Clathrand Inclusion Hosts
1.3 Halogenated Heteroaromatic Hosts2 Aromatic Edge-Edge C-H· · ·N Dimers; 3 Heteroatom-1,3-Peri Interactions; 3.1 The Ether-1,3-Peri Aromatic Hydrogen Interaction; 3.2 The Thioether-and Aza-1,3-Peri Aromatic Hydrogen Interactions; 4 Molecular Pen Structures; 5 Halogenated Edge-Edge Interactions; 6 Pi-Halogen Dimer (PHD) Interactions; 6.1 A New Aromatic Building Block; 6.2 Staircase Inclusion Compounds; 6.3 Layer Inclusion Compounds; 7 Molecular Bricks, Spheres and Grids; 7.1 Bricks and Mortar Inclusion Systems; 7.2 Molecular Spheres of Variable Composition; 7.3 Interlocking Molecular Grids
8 Conclusions
Record Nr. UNINA-9910830171803321
Chichester, England ; ; Hoboken, NJ, : Wiley, c2006
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Frontiers in crystal engineering / / edited by Edward R.T. Tiekink, Jagadese J. Vittal
Frontiers in crystal engineering / / edited by Edward R.T. Tiekink, Jagadese J. Vittal
Pubbl/distr/stampa Chichester, England ; ; Hoboken, NJ, : Wiley, c2006
Descrizione fisica 1 online resource (347 p.)
Disciplina 548
Altri autori (Persone) TiekinkEdward R. T
VittalJagadese J
Soggetto topico Molecular crystals - Research
ISBN 1-280-44877-6
9786610448777
0-470-02261-2
0-470-02259-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Frontiers in Crystal Engineering; Contents; List of Contributors; Foreword; 1 Applications of Crystal Engineering Strategies in Solvent-free Reactions: Toward a Supramolecular Green Chemistry; 1 Introduction; 1.1 Making Crystals by Smashing Crystals?; 1.2 Milling, Grinding, Kneading and Seeding; 2 Mechanochemical Preparation of Hydrogen-Bonded Adducts; 3 Mechanically Induced Formation of Covalent Bonds; 3.1 Mechanochemical Preparation of Coordination Networks; 4 The Solvent-free Chemistry of the Zwitterion [CoIII(η5-C5H4COOH)(η5-C5H4COO)]; 5 Concluding Remarks; 6 Acknowledgments; References
2 Crystal Engineering of Pharmaceutical Co-crystals1 Introduction; 1.1 What Are Co-crystals?; 1.2 How Are Co-crystals Prepared?; 1.3 Why Are Co-crystals of Relevance in the Context of APIs?; 2 What Is the Origin of Polymorphism and Is It Prevalent in Co-crystals?; 3 What Is a Pharmaceutical Co-crystal?; 3.1 A Case Study: Pharmaceutical Co-crystals of Carbamazepine, 1 (CBZ, 1); 3.2 But Beware of "Fake" Pharmaceutical Co-crystals!; 4 Conclusions; 5 Acknowledgments; References; 3 Template-controlled Solid-state Synthesis: Toward a General Form of Covalent Capture in Molecular Solids
1 Introduction1.1 Target-oriented Organic Synthesis; 1.2 Target-oriented Organic Synthesis and Covalent Capture; 1.3 Overview; 2 Controlling Reactivity Using Linear Templates; 3 Template-controlled Solid-state Reactivity; 3.1 Template-controlled Reactivity in the Solid state; 3.2 Resorcinol as a Linear Template; 3.3 Modularity and Generality; 4 Target-oriented Organic Synthesis in the Solid State; 4.1 [2.2]-Paracyclophane; 4.2 Template Switching; 4.3 Ladderanes; 5 Other Linear Templates; 5.1 1,8-Naphthalenedicarboxylic Acid; 5.2 Bis-p-phenylene[34]-crown[10]
5.3 Carballylic and 1,2,4,5-Benzenetetracarboxylic Acids5.4 Tetrakis(4-iodoperfluorophenyl)erythritol; 6 Summary and Outlook; References; 4 Interplay of Non-covalent Bonds: Effect of Crystal Structure on Molecular Structure; 1 Introduction; 2 Second-Sphere Coordination; 3 Soft Coordination Environments; 3.1 Mercury and Tin; 3.2 Comparison with Calculation; 3.3 Influence of Disorder; 4 Speciation; 5 Molecular Conformation; 6 Conclusions; References; 5 Crystal Engineering of Halogenated Heteroaromatic Clathrate Systems; 1 Introduction; 1.1 Clathrates; 1.2 New Clathrand Inclusion Hosts
1.3 Halogenated Heteroaromatic Hosts2 Aromatic Edge-Edge C-H· · ·N Dimers; 3 Heteroatom-1,3-Peri Interactions; 3.1 The Ether-1,3-Peri Aromatic Hydrogen Interaction; 3.2 The Thioether-and Aza-1,3-Peri Aromatic Hydrogen Interactions; 4 Molecular Pen Structures; 5 Halogenated Edge-Edge Interactions; 6 Pi-Halogen Dimer (PHD) Interactions; 6.1 A New Aromatic Building Block; 6.2 Staircase Inclusion Compounds; 6.3 Layer Inclusion Compounds; 7 Molecular Bricks, Spheres and Grids; 7.1 Bricks and Mortar Inclusion Systems; 7.2 Molecular Spheres of Variable Composition; 7.3 Interlocking Molecular Grids
8 Conclusions
Record Nr. UNINA-9910876756503321
Chichester, England ; ; Hoboken, NJ, : Wiley, c2006
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The importance of Pi-interactions in crystal engineering [[electronic resource] ] : frontiers in crystal engineering / / edited by Edward R.T. Tiekink, Júlio Zukerman-Schpector
The importance of Pi-interactions in crystal engineering [[electronic resource] ] : frontiers in crystal engineering / / edited by Edward R.T. Tiekink, Júlio Zukerman-Schpector
Edizione [2nd ed.]
Pubbl/distr/stampa Hoboken, NJ, : Wiley, 2012
Descrizione fisica 1 online resource (402 p.)
Disciplina 548/.3
Altri autori (Persone) TiekinkEdward R. T
Zukerman-SchpectorJúlio
Soggetto topico Molecular crystals
Supramolecular organometallic chemistry
Crystal growth
ISBN 1-119-94092-3
1-280-59152-8
9786613621351
1-119-94588-7
1-119-94589-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto The Importance of Pi-Interactions in Crystal Engineering; Contents; Preface; List of Contributors; 1 The CH/p Hydrogen Bond: Implication in Crystal Engineering; 1.1 Introduction; 1.1.1 Evidence and the Nature of the CH/p Hydrogen Bond; 1.1.2 Directionality of the CH/p Hydrogen Bond; 1.2 Cooperative Effect of the CH/p Hydrogen Bond; 1.2.1 Cooperative Effect as Evidenced by High-Level Ab Initio MO Calculations; 1.2.2 Cooperative Effect as Evidenced by Periodic Ab Initio MO Calculations; 1.2.3 Cooperative Effect as Evidenced by Stabilisation of Materials in Aromatic Nanochannels
1.2.4 Optical Resolution 1.3 CH/p Hydrogen Bonds in Supramolecular Chemistry; 1.3.1 Crystal Packing; 1.3.2 Lattice Inclusion Type Clathrates; 1.3.3 Cavity Inclusion Type Clathrates; 1.4 Crystallographic Database Analyses; 1.4.1 CH/p Hydrogen Bonds as Evidenced by CSD Analyses; 1.4.2 Systematic CSD Analyses; 1.5 Systematic CSD Analyses of the CH/p Hydrogen Bond; 1.5.1 Method and General Survey of Organic Molecules; 1.5.2 Organometallic Compounds; 1.6 Summary and Outlook; Acknowledgments; References; 2 New Aspects of Aromatic p. . . p and C-H . . . p Interactions in Crystal Engineering
2.1 Introduction 2.1.1 Planar Aromatic Molecules; 2.1.2 Edge-Face (EF) and Offset Face-Face (OFF) Interactions; 2.1.3 Competition between EF and OFF Interactions; 2.1.4 Edge-Edge (EE) Interactions; 2.2 Three-Dimensional Aromatic Structures; 2.2.1 Aryl . . . Aryl Embrace Interactions; 2.2.2 Design of Heteroaromatic Inclusion Hosts; 2.3 Endo,Endo-Facial Dimers; 2.3.1 The Basic P4AE Interaction Motif; 2.3.2 Discrete Endo,Endo-Facial Dimers; 2.3.3 Aggregated Endo,Endo-Facial Dimers; 2.4 Multiply Halogenated Heteroaromatic Molecules; 2.4.1 The p-Halogen Dimer (PHD) Interaction
2.4.2 The PHD Unit in Staircase Inclusion Structures 2.4.3 The PHD Unit in Layer Structures; 2.4.4 Switch from Endo,Endo-Facial Dimer to PHD Unit; 2.5 Expansion of the Endo,Endo-Facial Dimer; 2.5.1 Penannular Guest Enclosure; 2.5.2 Types of Molecular Pens; 2.6 (EF)6 Brick-Like Building Blocks; 2.6.1 Phenylated Heteroaromatic Molecules; 2.6.2 Packing of the Bricks; 2.6.3 Different Inclusion Families and Their Convergence; 2.7 Other Novel Multiple Edge-Face Assemblies; 2.7.1 The (EF)2 Handclasp Interaction; 2.7.2 Formation of Hexameric Inclusion Capsules
2.7.3 Formation of Hexameric Hydrate Clusters 2.8 Other Types of Aryl-Aryl Contacts; 2.8.1 Different OFF Packing Geometries; 2.8.2 Exo,Endo-Facial OFF Interactions; 2.8.3 Exo,Exo-Facial OFF Interactions; 2.8.4 Swivel Interactions; 2.9 Conclusions; Acknowledgments; References; 3 CH-p and p-p Interactions as Contributors to the Guest Binding in Reversible Inclusion and Encapsulation Complexes; 3.1 Introduction; 3.1.1 Theoretical Considerations of Aromatic-Aromatic (p-p) Interactions and CH-p Interactions
3.2 Probing Aromatic-Aromatic (p-p) Interactions and CH-p Interactions with Solid-State Structures of Reversible Inclusion and Encapsulation Complexes
Record Nr. UNINA-9910141316503321
Hoboken, NJ, : Wiley, 2012
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The importance of Pi-interactions in crystal engineering : frontiers in crystal engineering / / edited by Edward R.T. Tiekink, Julio Zukerman-Schpector
The importance of Pi-interactions in crystal engineering : frontiers in crystal engineering / / edited by Edward R.T. Tiekink, Julio Zukerman-Schpector
Edizione [2nd ed.]
Pubbl/distr/stampa Hoboken, NJ, : Wiley, 2012
Descrizione fisica 1 online resource (402 p.)
Disciplina 548/.3
Altri autori (Persone) TiekinkEdward R. T
Zukerman-SchpectorJulio
Soggetto topico Molecular crystals
Supramolecular organometallic chemistry
Crystal growth
ISBN 1-119-94092-3
1-280-59152-8
9786613621351
1-119-94588-7
1-119-94589-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto The Importance of Pi-Interactions in Crystal Engineering; Contents; Preface; List of Contributors; 1 The CH/p Hydrogen Bond: Implication in Crystal Engineering; 1.1 Introduction; 1.1.1 Evidence and the Nature of the CH/p Hydrogen Bond; 1.1.2 Directionality of the CH/p Hydrogen Bond; 1.2 Cooperative Effect of the CH/p Hydrogen Bond; 1.2.1 Cooperative Effect as Evidenced by High-Level Ab Initio MO Calculations; 1.2.2 Cooperative Effect as Evidenced by Periodic Ab Initio MO Calculations; 1.2.3 Cooperative Effect as Evidenced by Stabilisation of Materials in Aromatic Nanochannels
1.2.4 Optical Resolution 1.3 CH/p Hydrogen Bonds in Supramolecular Chemistry; 1.3.1 Crystal Packing; 1.3.2 Lattice Inclusion Type Clathrates; 1.3.3 Cavity Inclusion Type Clathrates; 1.4 Crystallographic Database Analyses; 1.4.1 CH/p Hydrogen Bonds as Evidenced by CSD Analyses; 1.4.2 Systematic CSD Analyses; 1.5 Systematic CSD Analyses of the CH/p Hydrogen Bond; 1.5.1 Method and General Survey of Organic Molecules; 1.5.2 Organometallic Compounds; 1.6 Summary and Outlook; Acknowledgments; References; 2 New Aspects of Aromatic p. . . p and C-H . . . p Interactions in Crystal Engineering
2.1 Introduction 2.1.1 Planar Aromatic Molecules; 2.1.2 Edge-Face (EF) and Offset Face-Face (OFF) Interactions; 2.1.3 Competition between EF and OFF Interactions; 2.1.4 Edge-Edge (EE) Interactions; 2.2 Three-Dimensional Aromatic Structures; 2.2.1 Aryl . . . Aryl Embrace Interactions; 2.2.2 Design of Heteroaromatic Inclusion Hosts; 2.3 Endo,Endo-Facial Dimers; 2.3.1 The Basic P4AE Interaction Motif; 2.3.2 Discrete Endo,Endo-Facial Dimers; 2.3.3 Aggregated Endo,Endo-Facial Dimers; 2.4 Multiply Halogenated Heteroaromatic Molecules; 2.4.1 The p-Halogen Dimer (PHD) Interaction
2.4.2 The PHD Unit in Staircase Inclusion Structures 2.4.3 The PHD Unit in Layer Structures; 2.4.4 Switch from Endo,Endo-Facial Dimer to PHD Unit; 2.5 Expansion of the Endo,Endo-Facial Dimer; 2.5.1 Penannular Guest Enclosure; 2.5.2 Types of Molecular Pens; 2.6 (EF)6 Brick-Like Building Blocks; 2.6.1 Phenylated Heteroaromatic Molecules; 2.6.2 Packing of the Bricks; 2.6.3 Different Inclusion Families and Their Convergence; 2.7 Other Novel Multiple Edge-Face Assemblies; 2.7.1 The (EF)2 Handclasp Interaction; 2.7.2 Formation of Hexameric Inclusion Capsules
2.7.3 Formation of Hexameric Hydrate Clusters 2.8 Other Types of Aryl-Aryl Contacts; 2.8.1 Different OFF Packing Geometries; 2.8.2 Exo,Endo-Facial OFF Interactions; 2.8.3 Exo,Exo-Facial OFF Interactions; 2.8.4 Swivel Interactions; 2.9 Conclusions; Acknowledgments; References; 3 CH-p and p-p Interactions as Contributors to the Guest Binding in Reversible Inclusion and Encapsulation Complexes; 3.1 Introduction; 3.1.1 Theoretical Considerations of Aromatic-Aromatic (p-p) Interactions and CH-p Interactions
3.2 Probing Aromatic-Aromatic (p-p) Interactions and CH-p Interactions with Solid-State Structures of Reversible Inclusion and Encapsulation Complexes
Record Nr. UNINA-9910826322103321
Hoboken, NJ, : Wiley, 2012
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Metallotherapeutic drugs and metal-based diagnostic agents [[electronic resource] ] : the use of metals in medicine / / [edited by] Marcel Gielen, Edward R.T. Tiekink
Metallotherapeutic drugs and metal-based diagnostic agents [[electronic resource] ] : the use of metals in medicine / / [edited by] Marcel Gielen, Edward R.T. Tiekink
Pubbl/distr/stampa Hoboken, N.J., : Wiley, c2005
Descrizione fisica 1 online resource (644 p.)
Disciplina 615.23
615/.23
Altri autori (Persone) GielenM <1938-> (Marcel)
TiekinkEdward R. T
Soggetto topico Metals - Therapeutic use
Metals - Diagnostic use
Soggetto genere / forma Electronic books.
ISBN 1-280-23877-1
9786610238774
0-470-29820-0
0-470-86404-4
0-470-86405-2
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto METALLOTHERAPEUTIC DRUGS AND METAL-BASED DIAGNOSTIC AGENTS; Contents; List of Contributors; Preface; 1 (3)Li Lithium Metallotherapeutics; 1.1 Introduction; 1.2 The Inorganic Chemistry of Lithium; 1.3 Biology of Lithium; 1.3.1 The history of lithium therapeutics; 1.3.2 Lithium and the body; 1.4 Targets of Lithium; 1.4.1 Glycogen synthase kinase-3; 1.4.2 Inositol phosphate signalling; 1.5 Lithium Therapeutics; 1.5.1 Bipolar disorder and schizophrenia; 1.5.2 Alzheimer's disease; 1.5.3 Ischemia (stroke); 1.5.4 Adverse effects; Acknowledgements; References
2 (5)B Boron Compounds as Therapeutic Drugs2.1 Boron Neutron Capture Therapy; 2.2 Classes of Boron Compounds for Potential Use in BNCT; 2.2.1 DNA binders; 2.2.2 Boron-containing amino acids and related peptides; 2.2.3 Boron-containing nucleic acid precursors; 2.3 Phosphates, Phosphonates and Phosphoramidates; 2.4 Amines; 2.5 Boron Analogues of Pyrophosphates; 2.6 Boronated Polyamines; 2.7 Carbohydrates; 2.8 Lipoproteins; 2.9 Lipids and Phospholipids; 2.10 Radiation Sensitizers; 2.11 Cyclic Thiourea Derivatives
2.12 Central Nervous System (CNS) Depressants: Promazines, Hydantoins and Barbiturates2.13 Hydantoins and Barbiturates; 2.14 Oligonucleotide Antisense Agents; 2.15 Hormones; 2.16 Liposomes; 2.17 Conclusions; Acknowledgements; References; 3 (12)Mg The Role of Magnesium as a Metallotherapeutic Drug; 3.1 Introduction; 3.2 Magnesium as a Drug; 3.2.1 Gestational hypertension, preeclampsia and eclampsia; 3.2.2 Asthma; 3.2.3 Stroke; 3.2.4 Acute myocardial infarction; 3.2.5 Arrhythmias; 3.2.6 Miscellaneous; References; 4 (13)Al Aluminum Metallotherapeutics; 4.1 Introduction; 4.2 Adjuvants; 4.2.1 Alum
4.2.2 Al(OH)(3)4.2.3 Aluminum phosphate; 4.3 Antacids; 4.3.1 Aluminum hydroxide; 4.3.2 Aluminum glycinate; 4.3.3 Peptic ulcer disease; 4.3.4 Bismuth aluminum carbonate; 4.3.5 Bismuth-magnesium-sodium alumino-silicate; 4.4 Phosphate Binders; 4.4.1 Basic aluminum carbonate; 4.4.2 Alumino-silicates; 4.5 Alginate Raft Formulations; 4.6 Blistering Diseases in the Elderly; 4.7 Metabolic Diseases and Aluminum; 4.8 Anti-malarial Substances; 4.9 Potential Aluminum Toxicity; 4.10 Conclusions; References; 5 (14)Si Biological Activity of Organosilicon Compounds; 5.1 Introduction
5.2 Organosilicon Modification5.2.1 O-, S- and N-Silylation; 5.2.2 C-Silylation; 5.3 Sila Analogues; 5.4 Specific Organosilicon Compounds; References; 6 (20)Ca The Role of Calcium as a Metallotherapeutic Drug; 6.1 Introduction; 6.2 Calcium Homeostasis; 6.3 Hormonal Regulation of Calcium Metabolism; 6.4 Optimal Amount of Dietary Calcium Intake and Benefits of Calcium Supplementation; 6.5 Osteoporosis; 6.6 Hypertension; 6.7 Hypertension in Pregnancy and Preeclampsia; 6.8 Colon Cancer; 6.9 Weight Control and Regulation of Body Fat; 6.10 Periodontal Disease; 6.11 Kidney Stones
6.12 Calcium Supplements: Side Effects
Record Nr. UNINA-9910147221003321
Hoboken, N.J., : Wiley, c2005
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Metallotherapeutic drugs and metal-based diagnostic agents [[electronic resource] ] : the use of metals in medicine / / [edited by] Marcel Gielen, Edward R.T. Tiekink
Metallotherapeutic drugs and metal-based diagnostic agents [[electronic resource] ] : the use of metals in medicine / / [edited by] Marcel Gielen, Edward R.T. Tiekink
Pubbl/distr/stampa Hoboken, N.J., : Wiley, c2005
Descrizione fisica 1 online resource (644 p.)
Disciplina 615.23
615/.23
Altri autori (Persone) GielenM <1938-> (Marcel)
TiekinkEdward R. T
Soggetto topico Metals - Therapeutic use
Metals - Diagnostic use
ISBN 1-280-23877-1
9786610238774
0-470-29820-0
0-470-86404-4
0-470-86405-2
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto METALLOTHERAPEUTIC DRUGS AND METAL-BASED DIAGNOSTIC AGENTS; Contents; List of Contributors; Preface; 1 (3)Li Lithium Metallotherapeutics; 1.1 Introduction; 1.2 The Inorganic Chemistry of Lithium; 1.3 Biology of Lithium; 1.3.1 The history of lithium therapeutics; 1.3.2 Lithium and the body; 1.4 Targets of Lithium; 1.4.1 Glycogen synthase kinase-3; 1.4.2 Inositol phosphate signalling; 1.5 Lithium Therapeutics; 1.5.1 Bipolar disorder and schizophrenia; 1.5.2 Alzheimer's disease; 1.5.3 Ischemia (stroke); 1.5.4 Adverse effects; Acknowledgements; References
2 (5)B Boron Compounds as Therapeutic Drugs2.1 Boron Neutron Capture Therapy; 2.2 Classes of Boron Compounds for Potential Use in BNCT; 2.2.1 DNA binders; 2.2.2 Boron-containing amino acids and related peptides; 2.2.3 Boron-containing nucleic acid precursors; 2.3 Phosphates, Phosphonates and Phosphoramidates; 2.4 Amines; 2.5 Boron Analogues of Pyrophosphates; 2.6 Boronated Polyamines; 2.7 Carbohydrates; 2.8 Lipoproteins; 2.9 Lipids and Phospholipids; 2.10 Radiation Sensitizers; 2.11 Cyclic Thiourea Derivatives
2.12 Central Nervous System (CNS) Depressants: Promazines, Hydantoins and Barbiturates2.13 Hydantoins and Barbiturates; 2.14 Oligonucleotide Antisense Agents; 2.15 Hormones; 2.16 Liposomes; 2.17 Conclusions; Acknowledgements; References; 3 (12)Mg The Role of Magnesium as a Metallotherapeutic Drug; 3.1 Introduction; 3.2 Magnesium as a Drug; 3.2.1 Gestational hypertension, preeclampsia and eclampsia; 3.2.2 Asthma; 3.2.3 Stroke; 3.2.4 Acute myocardial infarction; 3.2.5 Arrhythmias; 3.2.6 Miscellaneous; References; 4 (13)Al Aluminum Metallotherapeutics; 4.1 Introduction; 4.2 Adjuvants; 4.2.1 Alum
4.2.2 Al(OH)(3)4.2.3 Aluminum phosphate; 4.3 Antacids; 4.3.1 Aluminum hydroxide; 4.3.2 Aluminum glycinate; 4.3.3 Peptic ulcer disease; 4.3.4 Bismuth aluminum carbonate; 4.3.5 Bismuth-magnesium-sodium alumino-silicate; 4.4 Phosphate Binders; 4.4.1 Basic aluminum carbonate; 4.4.2 Alumino-silicates; 4.5 Alginate Raft Formulations; 4.6 Blistering Diseases in the Elderly; 4.7 Metabolic Diseases and Aluminum; 4.8 Anti-malarial Substances; 4.9 Potential Aluminum Toxicity; 4.10 Conclusions; References; 5 (14)Si Biological Activity of Organosilicon Compounds; 5.1 Introduction
5.2 Organosilicon Modification5.2.1 O-, S- and N-Silylation; 5.2.2 C-Silylation; 5.3 Sila Analogues; 5.4 Specific Organosilicon Compounds; References; 6 (20)Ca The Role of Calcium as a Metallotherapeutic Drug; 6.1 Introduction; 6.2 Calcium Homeostasis; 6.3 Hormonal Regulation of Calcium Metabolism; 6.4 Optimal Amount of Dietary Calcium Intake and Benefits of Calcium Supplementation; 6.5 Osteoporosis; 6.6 Hypertension; 6.7 Hypertension in Pregnancy and Preeclampsia; 6.8 Colon Cancer; 6.9 Weight Control and Regulation of Body Fat; 6.10 Periodontal Disease; 6.11 Kidney Stones
6.12 Calcium Supplements: Side Effects
Record Nr. UNINA-9910830892403321
Hoboken, N.J., : Wiley, c2005
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Metallotherapeutic drugs and metal-based diagnostic agents : the use of metals in medicine / / [edited by] Marcel Gielen, Edward R.T. Tiekink
Metallotherapeutic drugs and metal-based diagnostic agents : the use of metals in medicine / / [edited by] Marcel Gielen, Edward R.T. Tiekink
Pubbl/distr/stampa Hoboken, N.J., : Wiley, c2005
Descrizione fisica 1 online resource (644 p.)
Disciplina 615/.23
Altri autori (Persone) GielenM <1938-> (Marcel)
TiekinkEdward R. T
Soggetto topico Metals - Therapeutic use
Metals - Diagnostic use
ISBN 1-280-23877-1
9786610238774
0-470-29820-0
0-470-86404-4
0-470-86405-2
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto METALLOTHERAPEUTIC DRUGS AND METAL-BASED DIAGNOSTIC AGENTS; Contents; List of Contributors; Preface; 1 (3)Li Lithium Metallotherapeutics; 1.1 Introduction; 1.2 The Inorganic Chemistry of Lithium; 1.3 Biology of Lithium; 1.3.1 The history of lithium therapeutics; 1.3.2 Lithium and the body; 1.4 Targets of Lithium; 1.4.1 Glycogen synthase kinase-3; 1.4.2 Inositol phosphate signalling; 1.5 Lithium Therapeutics; 1.5.1 Bipolar disorder and schizophrenia; 1.5.2 Alzheimer's disease; 1.5.3 Ischemia (stroke); 1.5.4 Adverse effects; Acknowledgements; References
2 (5)B Boron Compounds as Therapeutic Drugs2.1 Boron Neutron Capture Therapy; 2.2 Classes of Boron Compounds for Potential Use in BNCT; 2.2.1 DNA binders; 2.2.2 Boron-containing amino acids and related peptides; 2.2.3 Boron-containing nucleic acid precursors; 2.3 Phosphates, Phosphonates and Phosphoramidates; 2.4 Amines; 2.5 Boron Analogues of Pyrophosphates; 2.6 Boronated Polyamines; 2.7 Carbohydrates; 2.8 Lipoproteins; 2.9 Lipids and Phospholipids; 2.10 Radiation Sensitizers; 2.11 Cyclic Thiourea Derivatives
2.12 Central Nervous System (CNS) Depressants: Promazines, Hydantoins and Barbiturates2.13 Hydantoins and Barbiturates; 2.14 Oligonucleotide Antisense Agents; 2.15 Hormones; 2.16 Liposomes; 2.17 Conclusions; Acknowledgements; References; 3 (12)Mg The Role of Magnesium as a Metallotherapeutic Drug; 3.1 Introduction; 3.2 Magnesium as a Drug; 3.2.1 Gestational hypertension, preeclampsia and eclampsia; 3.2.2 Asthma; 3.2.3 Stroke; 3.2.4 Acute myocardial infarction; 3.2.5 Arrhythmias; 3.2.6 Miscellaneous; References; 4 (13)Al Aluminum Metallotherapeutics; 4.1 Introduction; 4.2 Adjuvants; 4.2.1 Alum
4.2.2 Al(OH)(3)4.2.3 Aluminum phosphate; 4.3 Antacids; 4.3.1 Aluminum hydroxide; 4.3.2 Aluminum glycinate; 4.3.3 Peptic ulcer disease; 4.3.4 Bismuth aluminum carbonate; 4.3.5 Bismuth-magnesium-sodium alumino-silicate; 4.4 Phosphate Binders; 4.4.1 Basic aluminum carbonate; 4.4.2 Alumino-silicates; 4.5 Alginate Raft Formulations; 4.6 Blistering Diseases in the Elderly; 4.7 Metabolic Diseases and Aluminum; 4.8 Anti-malarial Substances; 4.9 Potential Aluminum Toxicity; 4.10 Conclusions; References; 5 (14)Si Biological Activity of Organosilicon Compounds; 5.1 Introduction
5.2 Organosilicon Modification5.2.1 O-, S- and N-Silylation; 5.2.2 C-Silylation; 5.3 Sila Analogues; 5.4 Specific Organosilicon Compounds; References; 6 (20)Ca The Role of Calcium as a Metallotherapeutic Drug; 6.1 Introduction; 6.2 Calcium Homeostasis; 6.3 Hormonal Regulation of Calcium Metabolism; 6.4 Optimal Amount of Dietary Calcium Intake and Benefits of Calcium Supplementation; 6.5 Osteoporosis; 6.6 Hypertension; 6.7 Hypertension in Pregnancy and Preeclampsia; 6.8 Colon Cancer; 6.9 Weight Control and Regulation of Body Fat; 6.10 Periodontal Disease; 6.11 Kidney Stones
6.12 Calcium Supplements: Side Effects
Record Nr. UNINA-9910877338303321
Hoboken, N.J., : Wiley, c2005
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Organic crystal engineering : frontiers in crystal engineering / / editors, Edward Tiekink, Jagadese Vittal, Michael Zaworotko
Organic crystal engineering : frontiers in crystal engineering / / editors, Edward Tiekink, Jagadese Vittal, Michael Zaworotko
Pubbl/distr/stampa Hoboken, NJ, : Wiley, 2010
Descrizione fisica 1 online resource (345 p.)
Disciplina 547
548
Altri autori (Persone) TiekinkEdward R. T
VittalJagadese J
ZaworotkoMichael
Soggetto topico Molecular crystals - Research
Organic solid state chemistry
Crystal growth
ISBN 1-282-48308-0
9786612483080
0-470-68179-9
0-470-68180-2
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Organic Crystal Engineering; Contents; List of Contributors; Preface; 1. The Role of the Cambridge Structural Database in Crystal Engineering; 1.1 Introduction; 1.2 Organisation and Management of Crystallographic Information; 1.2.1 Validation of New Crystal Structures: Mogul; 1.2.2 Validation of Structural Discoveries: What is New and What is Not?; 1.3 Organisation of Crystallographic Information for Crystal Engineering; 1.3.1 IsoStar; 1.3.2 CSDContact; 1.3.3 CSDSymmetry; 1.4 New Tools for Database Research; 1.4.1 A General Tool for 3-D Searches of the CSD: 3DSEARCH; 1.4.2 Ad hoc Software
1.5 Search for Functional Group Exchanges: GRX1.6 Search for Solvated and Unsolvated Structures: Solvates; 1.6.1 Tools to Examine Structural Similarity; 1.7 Clustering and Classifying CSD Search Results: dSNAP; 1.8 The PXRD Profile as a Structural Descriptor; 1.8.1 IsoQuest; 1.8.2 Self-organising maps; 1.8.3 Discrimination of polymorphs and redeterminations; 1.9 Identifying Supramolecular Constructs: XPac; 1.10 Concluding Remarks: The Future Role of Crystallographic Databases; References; 2. Computational Crystal Structure Prediction: Towards In Silico Solid Form Screening; 2.1 Introduction
2.2 Methods used to Predict Crystal Structures2.2.1 Search Methods; 2.2.2 Evaluating the Computer-generated Crystal Structures; 2.3 Current Capabilities of Crystal Structure Prediction; 2.3.1 The Blind Tests; 2.3.2 Further Assessments of Crystal Structure Prediction; 2.3.3 Flexible Molecules; 2.4 Exploration of Crystal Forms. A Case Study: Carbamazepine; 2.4.1 Polymorphism and the Influence of Small Molecular Changes on Packing; 2.4.2 Solvate and Co-crystal Formation; 2.4.3 Computational Solid Form Screening?; 2.5 Summary; Acknowledgements; References
3. Multi-component Pharmaceutical Crystalline Phases: Engineering for Performance3.1 Introduction; 3.2 Exploring Crystal Form Diversity; 3.3 High-throughput Experimentation; 3.4 Examples of 'Form and Formulation'; 3.4.1 Indinavir sulfate ethanolate - a case of a salt hydrate/solvate; 3.4.2 Norfloxacin - polymorphs, solvates, salts, complexes and co-crystals; 3.5 AMG517 and Celecoxib - 'Spring and Parachute' Approach; 3.5.1 β-Lactam antibiotics and hydrates - the importance of crystallinity; 3.6 Carbamazepine - Stabilization Against a Hydrate
3.7 Theophylline:Phenobarbital - Two is Better Than One3.8 Delaviridine Mesylate - Material Misbehaviour; 3.9 Summary and Outlook; References; 4. Complex Formation of Surfactants with Aromatic Compounds and their Pharmaceutical Applications; 4.1 Introduction; 4.2 Structures of the Complexes Formed Between Surfactants and Aromatic Compounds; 4.2.1 Crystal structure of I (CTAB-p-hydroxybenzoic acid); 4.2.2 Crystal structure of II (CTAB-m-cyanophenol); 4.2.3 Crystal structure of III (CTAB-p-cresol); 4.2.4 Crystal structure of IV (CTAB-hydroquinone)
4.2.5 Crystal structure of V (CTAB-o-iodophenol)
Record Nr. UNINA-9910139502803321
Hoboken, NJ, : Wiley, 2010
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui